Skip to main content

Articles

ASCO 2020 - Lung Cancer

Combination of Nivolumab, Ipilimumab, and Chemotherapy in Metastatic NSCLC

ASCO 2020 - Lung Cancer

Retrospective Data Suggest Role for Immunotherapy in Patients with Large-Cell Neuroendocrine Carcinoma

ASCO 2020 - Lung Cancer

3-Year Follow-Up Data for Nivolumab Combined with Ipilimumab in Treatment-Naïve NSCLC: CheckMate-227

ASCO 2020 - Lung Cancer

Real-World Data for Nivolumab in Patients with Malignant Mesothelioma

ASCO 2020 - Lung Cancer

Immunotherapy Combined with Stereotactic Radiation in Early-Stage, Medically Inoperable NSCLC: Safety Analysis from I-SABR

ASCO 2020 - Lung Cancer

Meta-analysis of Checkpoint Inhibitor Trials in Front-Line NSCLC

ASCO 2020 - Lung Cancer

CheckMate-9LA Evaluates Addition of Chemotherapy to NIVO + IPI in First-Line Advanced NSCLC

FDA Approvals, Prostate Cancer

Lynparza First Targeted Therapy Approved for Metastatic Prostate Cancer with HRR Mutation

FDA Approvals, Lung Cancer, Oncology

Tecentriq Approved as First-Line Therapy for Metastatic NSCLC with High PD-L1 Expression

Bye Bye Burnout?

David B. Nash, MD, MBA

Page 36 of 244
Results 351 - 360 of 2436